Two-drug treatment for advanced pancreatic cancer with BRCA or PALB2 changes
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests two drugs (vilastobart and retifanlimab) for people with advanced pancreatic cancer who have a specific genetic change in BRCA1, BRCA2, or PALB2. The goal is to see if this drug combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of pancreatic cancer that has spread (metastatic) and a change in the BRCA1, BRCA2, or PALB2 gene (either inherited or in the tumor).
- You must have already received at least one but no more than two chemotherapy treatments for your cancer, and you must have had a platinum-based chemotherapy (like carboplatin or cisplatin) with at least stable disease.
- You must have tumors that can be measured and at least one tumor that can be safely biopsied. You will need to agree to a biopsy before and during treatment.
- You must be 18 or older and able to perform daily activities with some help (ECOG score 0-2).
- Your blood counts, liver, and kidney function must be within acceptable levels.
- You must agree to use effective birth control if applicable and not breastfeed during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (regorafenib, toripalimab, and albumin-bound paclitaxel) as a third-line treatment for advanced pancreatic cancer that has progressed after two prior therapies. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug (OMTX705) combined with standard chemotherapy (gemcitabine/nab-paclitaxel) and an immunotherapy (tislelizumab) for people with advanced pancreatic cancer. It may be an option if you have had little or no prior chemotherapy.
This trial tests a new combination of drugs (including an investigational immunotherapy and a targeted pill, plus standard chemotherapy) as the first treatment for pancreatic cancer that cannot be removed with surgery. It may help shrink tumors or slow the cancer's growth.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Hear when a new Pancreatic Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.